Buy Tesamorelin Online
Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH) best known for research into growth-hormone signaling, visceral adipose tissue, liver fat, and metabolic health.
Its ability to stimulate endogenous GH release has made it one of the more extensively studied peptides affecting body-fat distribution.
Product Information
Tesamorelin is designed to activate GHRH receptors in the pituitary gland. This increases growth hormone secretion and subsequently influences IGF-1 levels.
Unlike direct growth hormone administration, Tesamorelin works upstream by stimulating the body’s own GH-producing pathway.
How Does Tesamorelin Work?
Tesamorelin activates GHRH receptors, increasing endogenous growth hormone release. The resulting GH/IGF-1 signaling influences lipid metabolism and fat distribution.
Tesamorelin Benefits
Reduces Visceral Adipose Tissue:
Tesamorelin has demonstrated a measurable reduction in visceral abdominal fat in randomized clinical trials. This effect is one of the strongest areas of human evidence surrounding the peptide.
Supports Liver-Fat Research:
Clinical research has also examined Tesamorelin for reducing hepatic fat. Studies have reported significant reductions in liver fat compared with placebo, making the peptide relevant to metabolic and liver-health research.
Influences GH/IGF-1 and Metabolic Pathways:
Tesamorelin increases GH and IGF-1 activity while influencing lipid metabolism. Research has also examined associated changes in triglycerides and other metabolic markers.
Tesamorelin Dosage
The most established human research dose is 2 mg once daily by subcutaneous injection. This is also the dose most commonly referenced in clinical and peptide-practice material for Tesamorelin.
Tesamorelin Side Effects
Common effects include injection-site reactions, joint pain, muscle aches, headache, swelling, and numbness or tingling. Because Tesamorelin raises GH/IGF-1 activity, changes in glucose control can also occur.
Research References
Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. PMID: 18057338.
PubMed
Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. PMID: 25038357.
PubMed
Purerawz Disclaimer
Purerawz does not sell, manufacture, stock, dispense, or directly supply any of the products discussed on this website. Purerawz is an affiliate-information website and may provide affiliate links to independent third-party suppliers.
The information provided in these pages is intended for educational and informational purposes only and should not be considered medical advice, diagnosis, or a recommendation to use any peptide. Research doses are included to describe published study protocols and are not individualized dosing instructions. Product quality, formulation, purity, route of administration, regulatory status, and availability may vary between suppliers and jurisdictions.
